Get the Stockscreener App
1.10
0.08%
-0.0009
After Hours:
1.11
0.01
+0.91%
Dermata Therapeutics Inc stock is traded at $1.10, with a volume of 12,751.
It is down -0.08% in the last 24 hours and down -26.17% over the past month.
Dermata Therapeutics Inc is a clinical-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to develop and formulate singular and combination products that are able to target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases.
See More
Previous Close:
$1.1009
Open:
$1.17
24h Volume:
12,751
Relative Volume:
0.02
Market Cap:
$2.30M
Revenue:
-
Net Income/Loss:
$-9.82M
P/E Ratio:
-0.1372
EPS:
-8.02
Net Cash Flow:
$-7.75M
1W Performance:
-5.17%
1M Performance:
-26.17%
6M Performance:
-67.46%
1Y Performance:
-88.43%
1-Day Range:
$1.10
$1.17
1-Week Range:
$1.07
$1.24
52-Week Range:
$1.0501
$13.35
Dermata Therapeutics Inc Stock (DRMA) Company Profile
Name
Dermata Therapeutics Inc
Sector
Industry
Phone
(858)-223-0882
Address
3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO
Compare DRMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DRMA
Dermata Therapeutics Inc
|
1.10 | 2.30M | 0 | -9.82M | -7.75M | -8.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Dermata Therapeutics Inc Stock (DRMA) Latest News
ARMISTICE CAPITAL, LLC Increases Stake in Dermata Therapeutics I - GuruFocus.com
Dermata Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Dermata Therapeutics stock hits 52-week low at $1.2 amid steep decline - Investing.com UK
Earnings Flash (DRMA) DERMATA THERAPEUTICS Reports Q3 Loss $-2.04 - Marketscreener.com
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results - AccessWire
Dermata Hits 50% Enrollment in Phase 3 Acne Trial, Raises $7.8M in 2024 | DRMAW Stock News - StockTitan
Dermata Therapeutics to Present at the Life Sciences Investor Forum on Thursday, November 14, 2024 - The Manila Times
Dermata stock hits 52-week low at $1.22 amid market challenges - Investing.com Australia
Sponge Power: Dermata's Revolutionary Acne Treatment Trial Results Due In 2025 - RTTNews
Analyzing DRMA’s price-to-book ratio for the last quarter - US Post News
Dermata stock hits 52-week low at $1.28 amid market challenges - Investing.com UK
Acne Vulgaris Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2024-2034), States DelveInsight | Clinuvel Pharma, Novan, Dermata Therapeutics, ioPharmX, Bausch Health - Barchart
Dermata Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024 - AccessWire
Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 3.2% - Defense World
How does Dianthus Therapeutics Inc (DNTH) change from a tortoise to a hare? - SETE News
Ameritas Investment Partners Inc. Has $1.82 Million Stake in Dolby Laboratories, Inc. (NYSE:DLB) - Defense World
How to interpret Design Therapeutics Inc (DSGN)’s stock chart patterns - US Post News
The Dixie Group (NASDAQ:DXYN) Earns Hold Rating from Analysts at StockNews.com - Defense World
Darden Restaurants, Inc. (NYSE:DRI) Holdings Raised by XTX Topco Ltd - Defense World
Darden shares steady on neutral rating from Piper Sandler - Investing.com India
Darden stock 'ready to run' with delivery boost and sales initiativesBTIG By Investing.com - Investing.com South Africa
Ensysce Biosciences (NASDAQ:ENSC) Stock Quotes, Forecast and News Summary - Benzinga
Argent Trust Co Has $533,000 Stock Position in Darden Restaurants, Inc. (NYSE:DRI) - Defense World
Diamondback Energy 12.77M share Spot Secondary priced at $178.00 - TipRanks
Darden price target raised to $195 from $185 at Truist - TipRanks
Dianthus Therapeutics (NASDAQ:DNTH) Trading Up 7.5% - MarketBeat
Analytical Overview: Dermata Therapeutics Inc (DRMA)’s Ratios Tell a Financial Story - The Dwinnex
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc.DYN - Kilgore News Herald
A Look at Dermata Therapeutics Inc (DRMA) Shares in the Recent Past Indicates Growth - SETE News
Dermata Therapeutics Announces Closing of $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules - StockTitan
Dermata Therapeutics Announces $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules - StockTitan
Why Intel Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket - Benzinga
Dow Jumps Over 200 Points; NY Empire State Manufacturing Index Increases In September - Benzinga
Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket - Benzinga
Entero Therapeutics (NASDAQ:ENTO) Stock Quotes, Forecast and News Summary - Benzinga
Acne Vulgaris Market Size is Set for Rapid Growth as Innovative - openPR
Dermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024 - StockTitan
Prepare Yourself for Liftoff: Dermata Therapeutics Inc (DRMA) - SETE News
Can you now get a good deal on Dermata Therapeutics Inc’s shares? - US Post News
Daily Market Movement: Dermata Therapeutics Inc (DRMA) Sees a 1.16 Increase, Closing at 1.74 - The Dwinnex
Axillary Hyperhidrosis Market Expected to Experience Major - openPR
Maxim cuts Dermata Therapeutics stock target, retains buy on dilution risk - Investing.com India
Maxim Group Lowers Dermata Therapeutics (NASDAQ:DRMA) Price Target to $6.00 - Defense World
Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Lags Revenue Estimates - MSN
Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results - Yahoo Finance
3 Penny Stocks to Watch Now, 8/6/24 - TipRanks
Take off with Dermata Therapeutics Inc (DRMA): Get ready for trading - SETE News
Dermata Therapeutics expands offering by $505,000 - Investing.com Australia
Dermata Therapeutics Inc [DRMA] moved up 44.19: Why It’s Important - The DBT News
Daily Market Movement: Dermata Therapeutics Inc (DRMA) Sees a 44.19 Increase, Closing at 2.48 - The Dwinnex
Why did Dermata Therapeutics Inc (NASDAQ: DRMA) surge today ? - BP Journal
Dermata Therapeutics Inc Stock (DRMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):